Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100
- 7 March 1992
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 339 (8793) , 598-600
- https://doi.org/10.1016/0140-6736(92)90875-4
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- Poor response to simvastatin in familial defective apo-B-100The Lancet, 1991
- HMG CoA reductase inhibitorsCurrent Opinion in Lipidology, 1991
- Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemiaArchives of internal medicine (1960), 1991
- Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1987
- Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.Proceedings of the National Academy of Sciences, 1987
- Therapeutic Response to Lovastatin (Mevinolin) in Nonfamilial HypercholesterolemiaJAMA, 1986